US4064234A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and pharmaceutical preparation for the treatment of hypercholesterolemia
Assignee: Bristol Myers Co
•
Filing: 1976-11-26
•
Granted: 1977-12-20
•
Expires: 1996-11-26
Abstract
Abstract A composition for treatment of hypercholesterolemia contains clofibrate or a clofibrate derivative, a magnesium or aluminum ion contributing compound which forms substantially insoluble metal bile acid salts and, optionally, a basic anion exchange resin. The composition components combine to give synergistic effect.
Inventors
- 👤 Alan N. Howard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/21; A61K31/215; A61K33/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
85 words
A pharmaceutical composition for use in the treatment per os of hypercholesterolemia, which comprises a hypocholesteremic effective amount of a. a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and b. an ingestible non-toxic aluminum or magnesium salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 2
Dependent Claim
85 words
A pharmaceutical composition for use in the treatment per os of hypercholesterolemia, which comprises a hypocholesteremic effective amount of a. a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and b. an ingestible non-toxic aluminum or magnesium salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 3
Dependent Claim
29 words
A composition according to claim 1 wherein the total amount of non-toxic metal is from 4 to 15 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 4
Dependent Claim
22 words
A composition according to claim 1 wherein a non-toxic magnesium salt is employed with the p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 5
Dependent Claim
22 words
A composition according to claim 1 wherein a non-toxic aluminum salt is employed with the p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 6
Dependent Claim
39 words
A composition according to claim 1 wherein there is also present on or more ingestible non-toxic basic anion exchange resins, there being from 50 to 8000 grams of resin per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 7
Dependent Claim
20 words
A composition according to claim 5 wherein the anion exchange resin is selected from cholestyramine, colestipol or poly-[2-(diethyl-amino)ethyl]polyglycerylene dextran hydrochloride.
Claim 8
Dependent Claim
12 words
A composition according to claim 1 comprising ethyl p-chlorophenoxyisobutyrate and magnesium hydroxide.
Claim 9
Dependent Claim
12 words
A composition according to claim 1 comprising ethyl p-chlorophenoxyisobutyrate and aluminum hydroxide.
Claim 10
Independent Claim
92 words
A method for the treatment of hypercholesterolemia, in which there is administered to the patient per os a hypocholesteremic effective dose of a pharmaceutical composition comprising a. a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and b. an ingestible non-toxic aluminum or magnesium salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 11
Independent Claim
92 words
A method for the treatment of hypercholesterolemia, in which there is administered to the patient per os a hypocholesteremic effective dose of a pharmaceutical composition comprising a. a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and b. an ingestible non-toxic aluminum or magnesium salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 12
Dependent Claim
31 words
A method according to claim 9 wherein the composition contains a total amount of non-toxic metal from 4 to 15 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 13
Dependent Claim
24 words
A method according to claim 9 wherein the composition contains a magnesium salt in combination with the p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 14
Dependent Claim
24 words
A method according to claim 9 wherein the composition contains an aluminum salt in combination with the p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 15
Dependent Claim
39 words
A method according to claim 9 wherein the composition also contains one or more ingestible non-toxic basic anion exchange resins, there being from 50 to 8000 grams of resin per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 16
Dependent Claim
20 words
A method according to claim 13 wherein the anion exchange resin is selected from cholestyramine, colestipol or poly-[2-(diethyl-amino)ethyl]polyglycerylene dextran hydrochloride.
Claim 17
Dependent Claim
42 words
A method according to claim 9 wherein the composition comprises ethyl p-chlorophenoxyisobutyrate and magnesium hydroxide, said composition being administered in an amount sufficient to provide a daily dosage of about 1.5 g. of ethyl p-chlorophenoxyisobutyrate and about 2.4 g. of magnesium hydroxide.
Claim 18
Dependent Claim
42 words
A method according to claim 9 wherein the composition comprises ethyl p-chlorophenoxyisobutyrate and aluminum hydroxide, said composition being administered in an amount sufficient to provide a daily dosage of about 1.5 g. of ethyl p-chlorophenoxyisobutyrate and about 2.4 g. of aluminum hydroxide.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-12-19 | 1981-06-20 | 1981-12-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-12-19 | 1985-06-20 | 1985-12-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-12-19 | 1989-06-20 | 1989-12-20 | $7700.00 | Window Closed / Lapsed |